Prasugrel receives CHMP nod
This article was originally published in Scrip
Executive Summary
The EU's CHMPhas granted a positive opinion recommending approval of LillyandDaiichi Sankyo's novel antiplatelet therapy prasugrel (Efient, 5mg and 10mg film-coated tablets), giving a boost to the product which has twice seen delays in its US approval process. In Tokyo, shares in Daiichi Sankyo surged by nearly 6% on the news on December 19th, regaining some of the ground lost since September when the FDA failed to complete its review by the PDUFA user fee deadline.